ABSI Earnings Date: Nov 12, 2026 (Estimated) — Absci Corporation
NASDAQ · Healthcare · Biotechnology
Updated
When is ABSI's next earnings date?
Absci Corporation (ABSI) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.19 on revenue of $627,810.
How did ABSI do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Absci Corporation posted EPS of -$0.21 versus the -$0.19 estimate, a miss of 10.5%. Revenue was $318,000 against a $919,583 estimate. The stock's 1-day post-earnings move was +1.0%.
How much does ABSI stock move after earnings?
ABSI beat EPS estimates in 1 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.6% (up or down) in the day after earnings.
About Absci Corporation
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.19 | -0.21 | -10.53% | $318,000 | ❌ Miss | +0.96% | -5.95% | -12.43% |
| 2026-05-07 | Q1 2026 | -0.20 | -0.19 | +5.00% | $215,000 | ✅ Beat | +2.61% | -3.65% | +13.91% |
| 2026-03-24 | Q4 2025 | -0.17 | -0.20 | -17.65% | $650,000 | ❌ Miss | -2.99% | -0.33% | +31.89% |
| 2025-11-12 | Q3 2025 | -0.20 | -0.20 | +0.00% | $378,000 | ➖ Inline | -22.35% | -15.88% | +7.06% |
| 2025-08-12 | Q2 2025 | -0.20 | -0.24 | -20.00% | $593,000 | ❌ Miss | +5.05% | -11.78% | -7.74% |
| 2025-03-18 | Q4 2024 | -0.23 | -0.25 | -8.70% | $665,000 | ❌ Miss | -3.25% | -0.32% | -0.97% |
| 2024-08-14 | Q2 2024 | -0.19 | -0.22 | -15.79% | $1.3M | ❌ Miss | +10.99% | +16.62% | +4.56% |
| 2024-05-14 | Q1 2024 | -0.21 | -0.22 | -4.76% | $898,000 | ❌ Miss | -4.55% | -8.89% | -1.98% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY21 · $728K total
| Segment | Share | Revenue | YoY |
|---|---|---|---|
| Technology Development Revenue | 81.3% | $592K | — |
| Collaborative Revenue | 18.7% | $136K | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.